Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07227285 · ClinicalTrials.gov registry record · Phase 1
Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy
A Phase 1 study, sponsored by EG 427.
- Not yet
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT07227285: Clinical Trial Phase 1 study, sponsored by EG 427.
NCT07227285 is a Phase 1 study that has not yet begun recruiting, run by EG 427. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07227285, a Phase 1 study, has not yet begun recruiting, sponsored by EG 427.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The aim of this study is to continue following participants who have received EG110A during five years to know how it is tolerated in humans, any side-effects it may cause and what might be an effective dose over five years. All participants who have received at least one dose/injection of EG110A in a previous clinical study of EG110A will be asked to roll-over to this long-term follow-up study upon either early discontinuation from, or completion of, that study.
Primary Outcome
Any participant who has a reported treatment emergent serious adverse event (TESAE)
Interventions
- DRUG EG110A
- OTHER Urodynamics
- OTHER Patient-reported Outcome
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2026-04 |
| Est. Completion | 2031-04 |
| Phase | Phase 1 |
What is known before NCT07227285 opens enrollment
NCT07227285 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 3 interventions - of which EG110A is the first listed.
NCT07227285 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07227285 about?
NCT07227285 is a clinical study titled "Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy". The aim of this study is to continue following participants who have received EG110A during five years to know how it is tolerated in humans, any side-effects it may cause and what might be an effective dose over five years. All participants who have received at least one dose/injection of EG110A in...
What is the current status of trial NCT07227285?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2026-04. Estimated completion is 2031-04.
What interventions are being tested in trial NCT07227285?
The interventions under investigation include: EG110A (DRUG), Urodynamics (OTHER), Patient-reported Outcome (OTHER).
Who is sponsoring clinical trial NCT07227285?
This trial is sponsored by EG 427, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07227285's enrollment target sits among peer trials
16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia